Associations between hemoglobin levels and sarcopenia and its components: Results from the I-Lan longitudinal study.


Journal

Experimental gerontology
ISSN: 1873-6815
Titre abrégé: Exp Gerontol
Pays: England
ID NLM: 0047061

Informations de publication

Date de publication:
15 07 2021
Historique:
received: 21 03 2021
revised: 20 04 2021
accepted: 21 04 2021
pubmed: 1 5 2021
medline: 3 7 2021
entrez: 30 4 2021
Statut: ppublish

Résumé

As a biomarker for anemia and nutritional status, hemoglobin may play various roles in the development of sarcopenia, but studies evaluating these roles are scarce. Hence, this study aimed to explore the associations between hemoglobin levels and sarcopenia and its components and to determine optimal cutoffs of hemoglobin for identifying sarcopenia. Data from 730 participants identified from the I-Lan Longitudinal Aging Study were retrieved. Anemia was defined by the World Health Organization criteria as a hemoglobin level <13 g/dL in men and <12 g/dL in women, and anemia status was divided into 5 groups (1 g/dL below cutoff, 0-1 g/dL below cutoff, 0-1 g/dL above cutoff, 1-2 g/dL above cutoff, and 2 g/dL above cutoff) for trend analysis. Sarcopenia was defined by the Asian Working Group for Sarcopenia 2019 criteria. In total, 118 (16.2%) participants were anemic, and 62 (8.5%) participants were sarcopenic. A higher hemoglobin level was significantly associated with faster gait speed (p-trend, 0.037) and stronger handgrip strength (p-trend, 0.003). Anemia was significantly associated with sarcopenia (OR: 2.4, 95% CI: 1.2-4.9), weakness (OR: 1.6, 95% CI: 1.0-2.5) and slowness (OR: 2.0, 95% CI: 1.1-3.4). Stronger correlations between anemia and sarcopenia were found in men and those with severe disease burden. Hemoglobin levels were independently associated with sarcopenia, and the associations were stronger for muscle function than for muscle mass and in men than in women. Older adults with anemia had a higher risk of sarcopenia and muscle weakness, and further intervention studies are needed to clarify the causal relationship between anemia and sarcopenia.

Sections du résumé

BACKGROUND
As a biomarker for anemia and nutritional status, hemoglobin may play various roles in the development of sarcopenia, but studies evaluating these roles are scarce. Hence, this study aimed to explore the associations between hemoglobin levels and sarcopenia and its components and to determine optimal cutoffs of hemoglobin for identifying sarcopenia.
METHODS
Data from 730 participants identified from the I-Lan Longitudinal Aging Study were retrieved. Anemia was defined by the World Health Organization criteria as a hemoglobin level <13 g/dL in men and <12 g/dL in women, and anemia status was divided into 5 groups (1 g/dL below cutoff, 0-1 g/dL below cutoff, 0-1 g/dL above cutoff, 1-2 g/dL above cutoff, and 2 g/dL above cutoff) for trend analysis. Sarcopenia was defined by the Asian Working Group for Sarcopenia 2019 criteria.
RESULTS
In total, 118 (16.2%) participants were anemic, and 62 (8.5%) participants were sarcopenic. A higher hemoglobin level was significantly associated with faster gait speed (p-trend, 0.037) and stronger handgrip strength (p-trend, 0.003). Anemia was significantly associated with sarcopenia (OR: 2.4, 95% CI: 1.2-4.9), weakness (OR: 1.6, 95% CI: 1.0-2.5) and slowness (OR: 2.0, 95% CI: 1.1-3.4). Stronger correlations between anemia and sarcopenia were found in men and those with severe disease burden.
CONCLUSIONS
Hemoglobin levels were independently associated with sarcopenia, and the associations were stronger for muscle function than for muscle mass and in men than in women. Older adults with anemia had a higher risk of sarcopenia and muscle weakness, and further intervention studies are needed to clarify the causal relationship between anemia and sarcopenia.

Identifiants

pubmed: 33930506
pii: S0531-5565(21)00161-3
doi: 10.1016/j.exger.2021.111379
pii:
doi:

Substances chimiques

Hemoglobins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

111379

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Sung-Hua Tseng (SH)

Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taipei, Taiwan; Aging and Health Research Center, National Yang Ming Chiao Tung University, Hsin-Chu, Taiwan; Department of Geriatric Medicine, National Yang Ming Chiao Tung University, School of Medicine, Hsin-Chu, Taiwan; Program of Molecular Medicine, National Yang Ming Chiao Tung University, Hsin-Chu, Taiwan.

Wei-Ju Lee (WJ)

Aging and Health Research Center, National Yang Ming Chiao Tung University, Hsin-Chu, Taiwan; Department of Geriatric Medicine, National Yang Ming Chiao Tung University, School of Medicine, Hsin-Chu, Taiwan; Department of Family Medicine, Taipei Veterans General Hospital Yuanshan Branch, Yi-Land, Taiwan. Electronic address: leewju@gmail.com.

Li-Ning Peng (LN)

Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taipei, Taiwan; Aging and Health Research Center, National Yang Ming Chiao Tung University, Hsin-Chu, Taiwan; Department of Geriatric Medicine, National Yang Ming Chiao Tung University, School of Medicine, Hsin-Chu, Taiwan.

Ming-Hsien Lin (MH)

Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taipei, Taiwan; Aging and Health Research Center, National Yang Ming Chiao Tung University, Hsin-Chu, Taiwan; Department of Geriatric Medicine, National Yang Ming Chiao Tung University, School of Medicine, Hsin-Chu, Taiwan.

Liang-Kung Chen (LK)

Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taipei, Taiwan; Aging and Health Research Center, National Yang Ming Chiao Tung University, Hsin-Chu, Taiwan; Department of Geriatric Medicine, National Yang Ming Chiao Tung University, School of Medicine, Hsin-Chu, Taiwan; Taipei Municipal Gan-Dau Hospital, Taipei, Taiwan. Electronic address: lkchen2@vghtpe.gov.tw.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH